Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?

Rene J. Duquesnoy

BACKGROUND: During the past three decades, HLA matching for platelet (PLT) transfusion of refractory thrombocytopenic patients has been based on serologic cross-reactivity between HLA-A and HLA-B antigens. Although many blood banks are using this matching strategy, the general experience is that such matched PLT transfusions are often ineffective.

STUDY DESIGN AND METHODS: This report describes a new HLA matching algorithm that considers structurally defined epitopes recognized by antibodies. HLAMatchmaker is a computer program that determines histocompatibility at the amino acid level initially designed as triplets (i.e., linear sequences of three residues in molecular surface-exposed positions) but now updated as eplets representing patches of antibody-accessible polymorphic residues surrounded by residues within a 3-Å radius. The eplet version of HLAMatchmaker is also useful in the analysis of HLA antibody reactivity patterns of alloimmunized patients so that acceptable mismatches can be identified.

CONCLUSION: An HLA epitope–based matching protocol is proposed that may permit a more effective PLT transfusion management of refractory patients. This protocol includes high-resolution HLA-A, -B, and -C typing of patients and donors, serum screening to identify acceptable mismatches, and the identification of suitable donors in a donor database that incorporates HLAMatchmaker as a search engine. HLAMatchmaker programs can be downloaded from the Web site http://tpis.upmc.edu/tpis/HLAMatchmaker/.

Aloimmunization against HLA Class I antigens has remained the major cause of refractoriness of thrombocytopenic patients to random-donor platelet (PLT) transfusions. Yankee and coworkers' first demonstrated in 1969 that alloimmunized patients can be successfully transfused with PLTs from HLA-identical donors. Duquesnoy together with Glenn Rodey and Richard Aster at the Milwaukee Blood Center applied the concept of serological cross-reactivity between HLA-A and HLA-B antigens to increase the number of potential donors. Although after 30 years, the so-called B1X, B1U, B2X, etc., match categories are still widely implemented by apheresis PLT transfusion services, this matching strategy is often enough ineffective.

Because alloimmunization-induced refractoriness is caused by antibodies, several investigators have applied different PLT cross-matching methods to select compatible PLTs mostly from the local inventory of the blood bank. This approach will also detect antibody reactivity against PLT-specific antigens but their specificity is difficult to determine in the presence of HLA antibodies. Another approach is to avoid PLTs with HLA antigens reacting specifically with the patient’s antibodies.

Obviously, the combination of matching for compatible antigens and the application of mismatch

ABBREVIATION: CREG = cross-reactive group.

From the Division of Transplantation Pathology, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Address reprint requests to: Rene J. Duquesnoy, PhD, University of Pittsburgh Medical Center, Thomas E. Starzl Biomedical Science Tower, Room W1552, Pittsburgh, PA 15261; e-mail: duquesnoyr@upmc.edu.

This study was supported by Grant AI-55933 from the National Institutes of Health.

Received for publication June 13, 2007; revision received July 12, 2007, and accepted July 12, 2007.


TRANSFUSION 2008;48:221-227.
acceptability determined by serum screening for HLA antibodies offers the best approach for an HLA-based PLT transfusion support of refractory patients. An important consideration is that HLA antigens have multiple epitopes that can be recognized by specific antibodies. During the 1980s, the description of epitope repertoire was based on serologic cross-reactivity between HLA antigens and antibody specificities against so-called private and public determinants. 

Serum screening of highly sensitized patients shows often restricted antibody specificity patterns against high-frequency public determinants. 

Elucidation of the stereochemical structure of the HLA molecule and determinations of amino acid sequences of HLA antigens made it possible to learn more about the structural basis of private and public determinants. This has led to many studies showing correlations between antibody specificity patterns and the presence of polymorphic amino acid residues on reactive HLA antigens. This concept was also applied to the analysis of serum samples from alloimmunized thrombocytopenic patients. 

STRUCTURALLY BASED HLA MATCHING

Matching at the single polymorphic residue level yielded, however, limited success. HLAMatchmaker represents an alternative structurally based matching algorithm that originally considered linear sequences of three amino acids (triplets) in antibody-accessible positions on HLA molecules; they can be considered key elements of epitopes that can induce the formation of specific antibodies. The patient’s own HLA antigens represent the repertoire of self-triplets to which no antibodies can be made and HLAMatchmaker determines for each mismatched HLA antigen, which triplets in corresponding sequence positions are different. The HLA phenotype of the recipient determines the degree of structural compatibility of a mismatched HLA antigen. For certain HLA phenotypes a given mismatch has no or few mismatched triplets and for other phenotypes, the same HLA antigen has many mismatched triplets and is therefore structurally highly incompatible.

The triplet matching concept has clinical relevance as indicated by a large database analysis that showed that HLA-A,B–mismatched kidneys that are compatible at the triplet level have practically the same graft survival rates as the zero HLA-A,B antigen mismatches defined by conventional criteria. This beneficial effect of triplet matching applies to both nonsensitized and sensitized patients and also to white and nonwhite patients. Thus, HLAMatchmaker can be used to increase the number of suitably matched kidney donors. An investigation at the National Institutes of Health Clinical Center has validated the potential of HLAMatchmaker in refining and expanding PLT donor selection for refractory, thrombocytopenic patients. Another study has also shown that triplet matching benefits PLT transfusions and makes better use of a limited donor pool.

HLAMatchmaker is also useful in the analysis of serum reactivity patterns with HLA panels. The group of Frans Claas in Leiden University Medical Center has demonstrated that the primary purpose of serum screening is the identification of acceptable mismatches for highly sensitized patients. This approach increases donor availability and leads to excellent graft survivals comparable to those seen with nonsensitized recipients. The application of HLAMatchmaker has enhanced the Acceptable Mismatch program and is now routinely used in Eurotransplant. The cumulative frequencies of self-antigens and acceptable mismatches can be used to calculate a PFD (probability of finding a donor) as an assessment of the transplantability of a sensitized patient.

DEVELOPMENT OF THE EPLET VERSION OF HLAMATCHMAKER

Although the triplet version of HLAMatchmaker has proven to be clinically useful, it provides an incomplete description of the structural HLA epitope repertoire. Expanded criteria must be used including longer sequences and polymorphic residues in discontinuous positions and they should consider the structural basis of antibody-antigen interactions including contact areas and binding energy, the essence of antigenicity.

A recent report describes the development of a structurally defined HLA epitope repertoire based on stereochemical modeling of crystallized complexes of antibodies with different protein antigens. This analysis considers the concept that antigenic proteins have functional epitopes consisting of amino acid residues that are about 3 Å apart from each other and at least one of them is non-self. There are 75 polymorphic positions on the surface of Class I HLA molecules, and a molecular viewer analysis has yielded a total of 199 so-called “eplets” on HLA-A, -B, and -C antigens. Another report describes the Class II eplet version of HLAMatchmaker. These computer programs can be downloaded from the Web site http://tpis.upmc.edu/tpis/HLAMatchmaker/.

Many eplets represent short linear sequences identical to those referred to as triplets but others have residues in discontinuous sequence positions that cluster together on the molecular surface. Serologically defined HLA determinants correspond well to eplets. The eplet version of HLAMatchmaker represents therefore a more complete repertoire of structurally defined HLA epitopes and provides a more detailed assessment of HLA compatibility.
LIMITATIONS OF THE CROSS-REACTIVITY BASED HLA MATCH GRADE SYSTEM FOR MANAGING REFRACTORY PATIENTS

The so-called Duquesnoy match grade system described in the AABB Technical Manual has three shortcomings that can be readily solved with HLAMatchmaker. The first one deals with groups of cross-reacting antigens that are used to assign the B1X, B1UX, B2X, etc., match grades. As an example, HLA-A2, HLA-A23, HLA-A24, HLA-A68, and HLA-A69 form the so-called A2 cross-reactive group (CREG) because they share a public epitope that corresponds to an eplet defined by 127K, that is, a lysine residue in the polymorphic position 127. Accordingly, A23 and A24 are B1X mismatches for A2. As shown in Table 1, these antigens have, however, considerable differences in their eplet makeup. For instance, A*2301 and A*2402 have the 79RI, 80IL, and 82LR eplets, which correspond to Bw4. (In the eplet notation system, a number indicates the sequence position of the polymorphic amino acid residue and the polymorphic residues within a 3-Å radius; residues are listed with the standard single-letter code.) Early studies had shown that Bw4 incompatibility may adversely affect PLT transfusion responses of refractory patients. The HLA type of the patient determines the acceptability of the Bw4-associated eplets on A*2301 and A*2402. These eplets would be unacceptable for a patient who types as HLA-A2,A3;B7,B8 but acceptable for a patient who types as HLA-A2,A25;B7,B8 because A25 has the 79RI, 80IL, and 82LR eplets. For the latter, acceptability of A*2301 and A*2402 would be overruled if the patient has antibodies against other eplets on these alleles such as 9S, 62EE, 65GKA, and others shown in Table 1, because each one has the potential of inducing specific antibodies. Similarly, A2, A68, and A69 are considered as a short A2 CREG (they uniquely share 142MT) but they have eplet differences in positions 9, 62, 65, etc. The degree of eplet matching depends on the HLA type of the patient and HLAMatchmaker can readily determine this.

The second limitation deals with the A, B1U, and B2U match groups, which are based on identity of serologically defined antigens and assume homozygosity for one or both loci. Molecular typing at the high-resolution or four-digit level has revealed additional subtypes (alleles) with amino acid sequence differences. Several of them involve antibody-accessible positions on the surface of the HLA molecule, and Table 2 shows examples of eplet differences between alleles. For instance, A*0203 has four eplet differences with A*0201, including 149TAH, which is also found on A25-, A26-, and A34-associated alleles. A*0203 would be a mismatch for patients who type for A*0201 and all other HLA-A antigens except A25, A26, and A34. Table 2 also shows that subtypes of antigens like A24, A30, B27, and B55 are not always matched at the epitope level.

**TABLE 1.** Eplet compositions of common alleles in the A2 cross-reactive group

<table>
<thead>
<tr>
<th>A*0201</th>
<th>9F†</th>
<th>11SV</th>
<th>14RR</th>
<th>30D</th>
<th>32Q</th>
<th>35RME</th>
<th>41A</th>
<th>44RM</th>
<th>46RME</th>
<th>56G</th>
<th>62GE†</th>
<th>65RKA†</th>
<th>66KAH†</th>
<th>71HS†</th>
</tr>
</thead>
<tbody>
<tr>
<td>A*2301</td>
<td>9S†</td>
<td>11SV</td>
<td>14RR</td>
<td>30D</td>
<td>32Q</td>
<td>35RME</td>
<td>41A</td>
<td>44RM</td>
<td>46RME</td>
<td>56G</td>
<td>62EE†</td>
<td>65GKA†</td>
<td>66KAH†</td>
<td>71HS†</td>
</tr>
<tr>
<td>A*2402</td>
<td>9S†</td>
<td>11SV</td>
<td>14RR</td>
<td>30D</td>
<td>32Q</td>
<td>35RME</td>
<td>41A</td>
<td>44RM</td>
<td>46RME</td>
<td>56G</td>
<td>62RN†</td>
<td>65RNA†</td>
<td>66NAQ†</td>
<td>71QS†</td>
</tr>
<tr>
<td>A*6901</td>
<td>9Y†</td>
<td>11SV</td>
<td>14RR</td>
<td>30D</td>
<td>32Q</td>
<td>35RME</td>
<td>41A</td>
<td>44RM</td>
<td>46RME</td>
<td>56G</td>
<td>62RN†</td>
<td>65RNA†</td>
<td>66NAQ†</td>
<td>71QS†</td>
</tr>
<tr>
<td>A*0201</td>
<td>73TD†</td>
<td>76VDT†</td>
<td>79GT†</td>
<td>80TR†</td>
<td>82RG†</td>
<td>90A</td>
<td>105S</td>
<td>107W†</td>
<td>109F</td>
<td>113YH†</td>
<td>116Y†</td>
<td>127K‡</td>
<td>131R</td>
<td>142MT†</td>
</tr>
<tr>
<td>A*2301</td>
<td>73TN†</td>
<td>76ENI†</td>
<td>79RI†</td>
<td>80IL†</td>
<td>82LR†</td>
<td>90A</td>
<td>105S</td>
<td>107G†</td>
<td>109F</td>
<td>113YH†</td>
<td>116Y†</td>
<td>127K‡</td>
<td>131R</td>
<td>142MI†</td>
</tr>
<tr>
<td>A*2402</td>
<td>73TN†</td>
<td>76ENI†</td>
<td>79RI†</td>
<td>80IL†</td>
<td>82LR†</td>
<td>90A</td>
<td>105S</td>
<td>107G†</td>
<td>109F</td>
<td>113YH†</td>
<td>116Y†</td>
<td>127K‡</td>
<td>131R</td>
<td>142MT†</td>
</tr>
<tr>
<td>A*6901</td>
<td>73TD†</td>
<td>76VDT†</td>
<td>79GT†</td>
<td>80TR†</td>
<td>82RG†</td>
<td>90A</td>
<td>105S</td>
<td>107W†</td>
<td>109F</td>
<td>113YH†</td>
<td>116Y†</td>
<td>127K‡</td>
<td>131R</td>
<td>142MT†</td>
</tr>
<tr>
<td>A*0201</td>
<td>144KH†</td>
<td>145HAA†</td>
<td>149AAH†</td>
<td>150AHV†</td>
<td>151HV†</td>
<td>158A</td>
<td>161E</td>
<td>163TW†</td>
<td>166EW</td>
<td>177ET</td>
<td>180Q</td>
<td>184A†</td>
<td>193AV†</td>
<td></td>
</tr>
<tr>
<td>A*2301</td>
<td>144QR†</td>
<td>145RAA†</td>
<td>149AAR†</td>
<td>150ARV†</td>
<td>151RV†</td>
<td>158A</td>
<td>161E</td>
<td>163TG†</td>
<td>166DG</td>
<td>177ET</td>
<td>180Q</td>
<td>184P†</td>
<td>193PI†</td>
<td></td>
</tr>
<tr>
<td>A*2402</td>
<td>144KR†</td>
<td>145RAA†</td>
<td>149AAH†</td>
<td>150ARV†</td>
<td>151RV†</td>
<td>158A</td>
<td>161E</td>
<td>163TW†</td>
<td>166EW</td>
<td>177ET</td>
<td>180Q</td>
<td>184A†</td>
<td>193AV†</td>
<td></td>
</tr>
<tr>
<td>A*6901</td>
<td>144KH†</td>
<td>145HAA†</td>
<td>149AAH†</td>
<td>150AHV†</td>
<td>151HV†</td>
<td>158A</td>
<td>161E</td>
<td>163TW†</td>
<td>166EW</td>
<td>177ET</td>
<td>180Q</td>
<td>184A†</td>
<td>193AV†</td>
<td></td>
</tr>
</tbody>
</table>

† The standard amino acid code is used to show the polymorphic residues in each eplet.
‡ The 127K eplet represents the public epitope shared by the members of the A2 CREG.

The structural HLA epitope matching in PLT transfusion support.
The third shortcoming of the CREG-based matching is that it considers only HLA-A and HLA-B antigens. The reason for excluding HLA-C is based on an early report that this locus plays no role in PLT transfusion responses. Moreover, it was believed that HLA-C antigens have low expression on PLTs. In those days HLA-C typing was done with serologic methods using inadequate typing sera defining a small number of HLA-C antigens. At present, complete HLA-C typing can be achieved with DNA-based methods. Recent studies have suggested that HLA-C matching might be necessary for the PLT transfusion support of some alloimmunized patients. This could best be done by HLA-C typing at the DNA level and by considering the structural basis of HLA-C epitopes. HLA-C alleles have a repertoire of more than 40 eplets. Certain eplets like 1C and 6K on Cw*0102 and 14W on Cw*0401, correspond to serologically defined antigens whereas many other eplets such as 21H on Cw*0202, Cw*0303, Cw*0304, and Cw*1502 are shared between two or more alleles and may represent public epitopes. HLAMatchmaker can determine HLA-C compatibility by comparing eplet strings of donor and recipient alleles. In our experience, serum screening with single-allele Luminex beads has shown HLA-C eplet-specific antibodies in HLA-sensitized patients.

### PROPOSAL FOR AN HLA EPITOPE MATCHING SYSTEM FOR PLT TRANSFUSIONS OF REFRACTORY PATIENTS

HLAMatchmaker can readily overcome the shortcomings of the CREG matching system because it provides a better assessment of histocompatibility. This algorithm considers HLA matching at the epitope level and applies the concept that HLA antibodies are specific for epitopes that can be structurally defined as eplets. Moreover, HLAMatchmaker can be used in the analysis of serum reactivity with HLA panels to determine the acceptability of HLA mismatches for alloimmunized patients. Table 3 represents an outline of a proposed HLA epitope–based matching protocol for PLT transfusion management of alloimmunization-induced refractoriness.
nation of HLA epitope repertoires. Often enough, HLA typing is only available at the serological or two-digit DNA level. In such cases, the most likely four-digit types could be estimated from allele frequencies in populations of individuals with the same racial or ethnic background. The HLAMatchmaker programs incorporate this approach.

Each patient suspected with HLA alloimmunization–induced refractoriness should be screened for HLA antibodies. The best approach is to use a combination of a complement-dependent method such as the direct and/or antiglobulin-augmented lymphocytotoxicity together with an antigen-binding assay such as Luminex, flow cytometry, and enzyme-linked immunosorbent assay (ELISA). Single HLA allele panels especially in the Luminex assays will generate the most informative reactivity patterns. The primary goal of a serum screen is to identify the acceptable HLA mismatches because this information offers a window of opportunity of finding more suitable donors for a refractory patient. The HLAMatchmaker-based analysis of serum reactivity patterns can determine which alleles have epitopes that do not react with the patient’s antibodies and these can be considered acceptable mismatches. The program will also identify additional alleles not used in the panel but which can be considered as acceptable mismatches. Conversely, HLAMatchmaker can also identify antibody-reactive epitopes and all such eplet-carrying alleles are unacceptable mismatches.

The identification of suitable donors can be readily done with a donor database that incorporates HLAMatchmaker as a search engine. Entering the patient’s HLA type and the mismatched alleles that do not react with the patient’s serum sample will generate a list of donors with matches and acceptable mismatches. Such donors do not need to be tested by labor-intensive PLT cross-matching for HLA incompatibilities. It is possible that insufficient numbers of donors are available for patients with uncommon HLA types and extremely high serum reactivity with the HLA panel. In such cases, the search could be extended to alleles with one or few mismatched eplets especially those with low immunogenicity. A few reports describe preliminary data about the relative immunogenicity of eplets (and triplets) but more studies are needed to obtain more complete information.

Although HLAMatchmaker is an epitope-based program for histocompatibility, it should be noted that donor match groups are presented as HLA alleles and are therefore easy to use in the practical setting. The success of any PLT transfusion depends on the resulting increment and the correction of the bleeding problem. Cases with low increments might be due to unrecognized HLA-related problems relative to serum screening results and erroneous interpretations of antibody reactivity patterns. With this improved HLA matching system, it would be easier to recognize other immunologic causes of low increment such as antibodies against PLT-specific antigens, autoimmune reactivity, and drug reactions. Nonimmune clinical conditions such as coagulopathy, sepsis, and hepatosplenomegaly are of course also frequent causes of low increments.

**PREVENTION OR DELAY OF HLA ALLOIMMUNIZATION**

The frequency of immune refractoriness has declined during the past decade largely due to the application of leukoreduction to PLT preparations and red cells before transfusion. Nevertheless, significant proportions of thrombocytopenic patients become refractory due to HLA alloimmunization. The latter problem can be minimized by providing long-term transfusion support with PLTs from HLA-matched apheresis donors. This strategy is impractical because not many such donors are available for most patients. Another approach is to apply HLAMatchmaker to identify donors with fewest possible epitope mismatches. The demonstration by the Leiden group of a strong correlation between the number of mismatched triplets and the degree of antibody sensitization induced by a kidney transplant or developed during pregnancy is relevant. This concept could be applied to the selection of inventoried PLTs with no or few eplet mismatches or, better yet, recruiting appropriately matched apheresis donors.

**CONCLUDING REMARKS**

The serologic cross-reacting antigen matching system introduced in 1977 should be replaced by a system that incorporates modern concepts of epitope reactivity with antibody. The proposed HLA epitope matching protocol is expected to benefit PLT transfusion outcome and increase the number of compatible donors for refractory patients. Three reports have provided evidence of the usefulness of HLAMatchmaker in selecting PLT donors. A prospective study at the National Blood Services in the United Kingdom is under way to evaluate the clinical efficacy of HLA epitope–matched PLT transfusions in aplastic anemia patients.

**REFERENCES**


2. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets “mismatched” for HLA


